Simple clinical predictors of stroke outcome based on National Institutes of Health Stroke Scale score during 1-h recombinant tissue-type plasminogen activator infusion

European Journal of Neurology

Volumn 21, Issue 3, 2014, Pages 411-418

  Osaki, M ^a   Miyashita, F ^a   Koga, M ^a   Fukuda, M ^a   Shigehatake, Y ^a   Nagatsuka, K ^a   Minematsu, K ^a   Toyoda, K ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Acute stroke; Neurological improvement; Outcomes; Recombinant tissue plasminogen activator; Thrombolysis

Indexed keywords

ACUTE STROKE; NEUROLOGICAL IMPROVEMENT; OUTCOMES; RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR; THROMBOLYSIS;

AGED; AGED, 80 AND OVER; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 84893868147     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12294     Document Type: Article

References (40)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1588
2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
3. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36: 1432-1438.
4. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008; 39: 1205-1212.
5. Penumbra Pivotal Stroke Trial Investigators. The Penumbra Pivotal Stroke Trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 2009; 40: 2761-2768.
6. Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus MERCI retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012; 380: 1231-1240.
7. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the MERCI Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012; 380: 1241-1249.
8. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013; 368: 893-903.
9. Ciccone A, Valvassori L, Nichelatti M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013; 368: 904-913.
10. Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013; 368: 914-923.
11. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55: 1649-1655.
12. Lees KR, Bluhmki E, von Kummer RD, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. The Lancet 2010; 375: 1695-1703.
13. Becktepe JS, You SJ, Berkefeld J, Neumann-Haefelin T, Singer OC. Clinical outcome after mechanical recanalization as mono- or adjunctive therapy in acute stroke: importance of time to recanalization. Cerebrovasc Dis 2011; 32: 211-218.
14. Felberg RA, Okon NJ, El-Mitwalli A, et al. Early dramatic recovery during intravenous tissue plasminogen activator infusion. Stroke 2002; 33: 1301-1307.
15. Broderick JP, Lu M, Kothari R, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 2000; 31: 2335-2341.
16. Brown DL, Johnston KC, Wagner DP, Haley EC. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 2004; 35: 147-150.
17. Nam HS, Lee K-Y, Han SW, et al. Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients. J Neurol Sci 2009; 281: 69-73.
18. Mori M, Naganuma M, Okada Y, et al. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rt-PA Registry. Cerebrovasc Dis 2012; 34: 140-146.
19. Muresan I-P, Favrole P, Levy P, et al. Very early neurologic improvement after intravenous thrombolysis. Arch Neurol 2010; 67: 1323-1328.
20. Lee K-Y, Han SW, Kim SH, et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients. Stroke 2007; 38: 192-193.
21. Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007; 38: 948-954.
22. Hirano T, Sasaki M, Mori E, et al. Residual vessel length on magnetic resonance angiography identifies poor responders to alteplase in acute middle cerebral artery occlusion patients. Exploratory analysis of Japan Alteplase Clinical Trial II. Stroke 2010; 41: 2828-2833.
23. Derex L, Hermier M, Adeleine P, et al. Influence of the site of arterial occlusion on multiple baseline hemodynamic MRI parameters and post-thrombolytic recanalization in acute stroke: a multicenter study. Neuroradiology 2004; 46: 883-887.
24. Kimura K, Iguchi Y, Shibazaki K, Aoki J, Uemura J. Early recanalization rate of major occluded brain arteries after intravenous tissue plasminogen activator therapy using serial magnetic resonance angiography studies. Eur Neurol 2009; 62: 287-292.
25. Nakashima T, Toyoda K, Koga M, et al. Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0·6 mg/kg) alteplase therapy for ischaemic stroke. Int J Stroke 2009; 4: 425-431.
26. Shinohara Y, Yanagihara T, Abe K, et al. II. Cerebral infarction/transient ischemic attack (TIA). J Stroke Cerebrovasc Dis 2011; 20: S31-S73.
27. Nezu T, Koga M, Kimura K, et al. Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry. Neurology 2010; 75: 555-561.
28. Nezu T, Koga M, Nakagawara J, et al. Early ischemic change on CT versus diffusion-weighted imaging for patients with stroke receiving intravenous recombinant tissue-type plasminogen activator therapy: Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rt-PA Registry. Stroke 2011; 42: 2196-2200.
29. Adams H, Bendixen B, Kappelle L, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
30. Mikulik R, Ribo M, Hill MD, et al. Accuracy of serial National Institutes of Health Stroke Scale scores to identify artery status in acute ischemic stroke. Circulation 2007; 115: 2660-2665.
31. Alexandrov AV, Hall CE, Labiche LA, Wojner AW, Grotta JC. Ischemic stunning of the brain: early recanalization without immediate clinical improvement in acute ischemic stroke. Stroke 2004; 35: 449-452.
32. von Kummer R, Holle R, Rosin L, Forsting M, Hacke W. Does arterial recanalization improve outcome in carotid territory stroke? Stroke 1995; 26: 581-587.
33. Mori E, Minematsu K, Nakagawara J, et al. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010; 41: 461-465.
34. Kharitonova T, Mikulik R, Roine RO, et al. Association of early National Institutes of Health Stroke Scale improvement with vessel recanalization and functional outcome after intravenous thrombolysis in ischemic stroke. Stroke 2011; 42: 1638-1643.
35. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283: 1145-1150.
36. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke - Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
37. Toyoda K, Koga M, Naganuma M, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke 2009; 40: 3591-3595.
38. Nakagawara J, Minematsu K, Okada Y, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41: 1984-1989.
39. Shobha N, Buchan AM, Hill MD. Thrombolysis at 3-4.5 hours after acute ischemic stroke onset - evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) Registry. Cerebrovasc Dis 2011; 31: 223-228.
40. Koga M, Arihiro S, Miyashita F, et al. Factors associated with early recanalization failure following intravenous rt-PA therapy for ischemic stroke. Cerebrovasc Dis 2013; 36: 299-305.